Cross-source evidence timeline

Petrelintide research timeline

Follow 12 selected, directly cited source records from January 28, 2026 through November 16, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

12Selected records
1Source years
2Evidence lanes
November 16, 2026Latest source date

Source year

2026

12 records
  1. Clinical trials

    ClinicalTrials.gov record NCT07843472↗

    PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was petrelintide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT07843485↗

    PeptideScanner retained ClinicalTrials.gov record NCT07843485 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was petrelintide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT07843498↗

    PeptideScanner retained ClinicalTrials.gov record NCT07843498 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was petrelintide.↗

  4. Literature metadata

    Petrelintide and the evolving role of amylin agonism in obesity.↗

    PubMed lists PMID 42810353 in The lancet. Diabetes & endocrinology as Journal Article, with publication-date metadata of 2026-09-29 (day precision). PeptideScanner associated the retained record with the identity slug petrelintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT06926842↗

    PeptideScanner retained ClinicalTrials.gov record NCT06926842 at 2026-09-09T19:17:17.080Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was petrelintide.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT07589686↗

    PeptideScanner retained ClinicalTrials.gov record NCT07589686 at 2026-08-13T05:52:27.014Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was petrelintide.↗

  7. Literature metadata

    PubMed record PMID 42017294↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 42017294 at 2026-08-10T18:13:48.775Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-04-22. PeptideScanner associated this retained record with the identity slug petrelintide. These dates describe PubMed metadata history, not the article's original publication date.↗

  8. Clinical trials

    Petrelintide combination study record posted↗

    ClinicalTrials.gov lists a Petrelintide study that is not yet recruiting sponsored by Hoffmann-La Roche.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT07682818↗

    PeptideScanner retained ClinicalTrials.gov record NCT07682818 at 2026-08-10T18:10:03.938Z. Its registry update date was 2026-07-06, and PeptideScanner's reviewed identity mapping was petrelintide.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT07338214↗

    PeptideScanner retained ClinicalTrials.gov record NCT07338214 at 2026-07-30T16:20:49.304Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was petrelintide.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT06662539↗

    PeptideScanner retained ClinicalTrials.gov record NCT06662539 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was petrelintide.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT07076030↗

    PeptideScanner retained ClinicalTrials.gov record NCT07076030 at 2026-07-30T16:25:18.009Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was petrelintide.↗